Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

NEXT STORY
RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING
PREV STORY
Allarity Therapeutics plans fully guaranteed rights issue of approximately SEK 100 million
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Advaxis Unveils State-of-the-art Manufacturing Facility, Laboratory to Produce and Develop Novel Immuno-Oncology Therapeutics

NJ Gov. Christie cuts ribbon, commends Advaxis milestone PRINCETON, N.J., Sept. 12, 2016 (GLOBE ...

author_avatar
NASDAQ Market News

Five Prime Therapeutics to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

author_avatar
NASDAQ Market News

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from ...

author_avatar
NASDAQ Market News